TLDR Revolut drops U.S. bank takeover plan, pivots to direct national license strategy. Digital-first vision drives Revolut’s switch to a de novo U.S. banking licenseTLDR Revolut drops U.S. bank takeover plan, pivots to direct national license strategy. Digital-first vision drives Revolut’s switch to a de novo U.S. banking license

Revolut Drops US Bank Takeover, Bets on Direct National Banking License

2026/01/23 23:45
3 min read

TLDR

  • Revolut drops U.S. bank takeover plan, pivots to direct national license strategy.
  • Digital-first vision drives Revolut’s switch to a de novo U.S. banking license.
  • Revolut targets faster U.S. entry by skipping costly bank acquisitions.
  • New U.S. plan strengthens Revolut’s global digital banking expansion drive.
  • Revolut reshapes U.S. roadmap to gain speed, control, and regulatory clarity.

Revolut has changed its US strategy and now plans to pursue a national banking license instead of buying a local bank. The company made the shift after it assessed the acquisition route and found slower timelines and higher operational demands.  The new plan positions Revolut to build a digital model without the limits of physical branches.

Revolut Walks Away from Takeover Plan

Revolut reviewed several chartered US banks but abandoned the approach because the process required extensive structural adjustments. The company expected a faster entry path, yet the findings showed greater complexity across regulatory and operational layers. Revolut determined that acquiring a bank would restrict its digital-only design and reduce its operational flexibility.

Revolut decided that a direct license application offers more control and clearer long-term benefits than a full takeover. This shift aligns with its effort to keep a lean model while still entering the largest financial market. The company stated that the US remains essential to its growth strategy.

Revolut reached a $75 billion valuation last year, and that milestone strengthened its ability to expand in major markets. The firm continues to broaden its banking reach despite limits on its UK license, which restrict its deposit base. Revolut maintains momentum across key regions and pursues new regulatory approvals.

De Novo License Moves Ahead Under New US Regulatory Climate

Revolut is applying for a de novo national banking license from the Office of the Comptroller of the Currency. The company believes the revamped agency may process applications faster, and this prospect supports its updated plan. The license would allow Revolut to tailor its US banking structure for a fully digital operation.

Revolut aims to secure lending rights nationwide and avoid dependence on state-by-state frameworks. This path offers unified oversight rather than the layered regimes that complicate market entry for global fintechs.  Recent charters granted to Circle and Ripple signal a wider opening for firms seeking national approval.

Revolut continues to assess several regulatory routes, yet the direct license now stands as its primary focus. The company aims to align its US plan with its broader global expansion program. It has not disclosed a timeline for the final filing process.

Revolut Expands Crypto and Global Banking Footprint

Revolut strengthened its European crypto presence through a new partnership that enables instant digital asset purchases with reduced fees. This move expands its platform features and supports rising demand across the region. Its MiCA license through Cyprus allows crypto activity across the European Economic Area.

Revolut is also pushing into Latin America through a banking license application in Peru. The region offers fast growth for mobile-led services, and the company aims to secure early scale. Additionally, Revolut is exploring an acquisition in Turkey to advance its entry into that market.

Revolut continues building a multi-market banking network while refining its US plans. The firm sees the direct license path as the most efficient way to anchor its American expansion. Therefore, its pivot marks a major strategic turn as it strengthens its global financial reach.

The post Revolut Drops US Bank Takeover, Bets on Direct National Banking License appeared first on CoinCentral.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26